Aduhelm reignites questions around ties between pharma and patient advocacy orgs
In the latest round of patient advocacy and the FDA, the drug reviewer approved Biogen and Eisai’s Alzheimer’s disease med Aduhelm over the advice of its own adcomm. Critics pointed to pressure from pharma-funded advocacy groups such as the Alzheimer’s Association and its social media campaigns as deciding factors. However, the Association and other groups who spoke up for a treatment maintain that they’re neutral and focus on patients’ needs and the need for treatment in the devastating disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
